1. The cristae modulator Optic atrophy 1 requires mitochondrial ATP synthase oligomers to safeguard mitochondrial function
- Author
-
Andrea Urbani, Charlotte Quirin, José Antonio Enríquez, Jesús Vázquez, Ruben Quintana-Cabrera, Enrique Calvo, Maria Eugenia Soriano, Mauro Corrado, Anna Pellattiero, Paolo Bernardi, Christina Glytsou, Luca Scorrano, Christoph Gerle, Fondazione Umberto Veronesi, Ministerio de Economía y Competitividad (España), Telethon Italia, Associazione Italiana per la Ricerca sul Cancro, European Research Council, European Commission, Ministero dell'Istruzione, dell'Università e della Ricerca, Japan Science and Technology Agency, Ministry of Education, Culture, Sports, Science and Technology (Japan), Consejo Superior de Investigaciones Científicas (España), Centro Nacional de Investigaciones Cardiovasculares (España), Enríquez, José Antonio, Vázquez, Jesús, Soriano, María Eugenia, Bernardi, Paolo, Scorrano, Luca, Italian Association for Cancer Research, Ministerio de Economía, Industria y Competitividad (España), Fondazione Telethon, Ministero dell Università e della Ricerca (Italia), Unión Europea. Comisión Europea, Ministry of Education, Culture, Sports, Science, and Technology (Japón), Fundación ProCNIC, Enríquez, José Antonio[0000-0002-3671-2961], Vázquez, Jesús[0000-0003-1461-5092], Soriano, María Eugenia [0000-0002-7971-2961], Bernardi, Paolo [0000-0001-9187-3736], and Scorrano, Luca [0000-0002-8515-8928]
- Subjects
0301 basic medicine ,Oligomycin ,Respiratory chain ,Antimycin A ,General Physics and Astronomy ,SUBUNIT-G ,Mitochondrion ,GTP Phosphohydrolases ,Mice ,chemistry.chemical_compound ,OXIDATIVE-PHOSPHORYLATION ,lcsh:Science ,INHIBITOR PROTEIN ,Multidisciplinary ,ATP synthase ,biology ,COMPLEX III DEFICIENCY ,Mitochondrial Proton-Translocating ATPases ,Mitochondria ,Cell biology ,mitochondrial fusion ,Optic Atrophy 1 ,PERMEABILITY TRANSITION PORE ,SUPRAMOLECULAR ORGANIZATION ,Electrophoresis, Polyacrylamide Gel ,CYTOCHROME-C RELEASE ,endocrine system ,Cell Survival ,Science ,Protein subunit ,Immunoblotting ,INNER MEMBRANE ,Article ,General Biochemistry, Genetics and Molecular Biology ,Mitochondrial Proteins ,03 medical and health sciences ,Microscopy, Electron, Transmission ,medicine ,Animals ,Immunoprecipitation ,LIVER-MITOCHONDRIA ,General Chemistry ,medicine.disease ,eye diseases ,F1F0-ATP SYNTHASE ,030104 developmental biology ,chemistry ,Coenzyme Q – cytochrome c reductase ,biology.protein ,lcsh:Q - Abstract
It is unclear how the mitochondrial fusion protein Optic atrophy 1 (OPA1), which inhibits cristae remodeling, protects from mitochondrial dysfunction. Here we identify the mitochondrial F1Fo-ATP synthase as the effector of OPA1 in mitochondrial protection. In OPA1 overexpressing cells, the loss of proton electrochemical gradient caused by respiratory chain complex III inhibition is blunted and this protection is abolished by the ATP synthase inhibitor oligomycin. Mechanistically, OPA1 and ATP synthase can interact, but recombinant OPA1 fails to promote oligomerization of purified ATP synthase reconstituted in liposomes, suggesting that OPA1 favors ATP synthase oligomerization and reversal activity by modulating cristae shape. When ATP synthase oligomers are genetically destabilized by silencing the key dimerization subunit e, OPA1 is no longer able to preserve mitochondrial function and cell viability upon complex III inhibition. Thus, OPA1 protects mitochondria from respiratory chain inhibition by stabilizing cristae shape and favoring ATP synthase oligomerization., R.Q.-C. was supported by an AIRC Postdoctoral Fellowship, a Fondazione Umberto Veronesi Postdoctoral Fellowship and is currently a recipient of a Juan de la Cierva-Incorporación fellowship from the Spanish Ministry of Economy, Industry and Competitiveness (IJCI-2015–26225). This work was supported by Telethon-Italy GPP10005, GGP14187, GGP15091; AIRC Italy IG-15748, ERC FP7-282280, FP7 CIG PCIG13-GA-2013-618697; Italian Ministry of Research FIRB RBAP11Z3YA_005 to L.S. C.Ge. is supported by JST, CREST Grant JPMJCR13M4 (to Genij Kurisu and C.Ge.), the Platform for Drug Design, Discovery and Development from MEXT, Japan and the Grants-in-Aid for Scientific Research (Kiban B: 17H03647) from MEXT, Japan. JAE is supported by Spanish Ministry of Economy, Industry and Competitiveness (SAF2015-65633-R; SAF2015-71521-REDC). The CNIC is supported by MINECO and Pro-CNIC Foundation and is a SO-MINECO (award SEV-2015-0505).
- Published
- 2018
- Full Text
- View/download PDF